Leerink Partnrs Expects Increased Earnings for Equillium

Equillium, Inc. (NASDAQ:EQ) – Equities researchers at Leerink Partnrs increased their FY2025 earnings estimates for shares of Equillium in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.83) per share for the year, up from their prior forecast of ($1.50). The consensus estimate for Equillium’s current full-year earnings is ($0.02) per share.

Equillium Stock Performance

NASDAQ EQ opened at $0.77 on Monday. The company’s 50-day simple moving average is $0.70 and its two-hundred day simple moving average is $0.81. Equillium has a one year low of $0.49 and a one year high of $3.25. The company has a market capitalization of $27.28 million, a price-to-earnings ratio of -5.50 and a beta of 1.79.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC lifted its position in Equillium, Inc. (NASDAQ:EQ) by 43.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 300,400 shares of the company’s stock after buying an additional 91,200 shares during the period. Renaissance Technologies LLC owned approximately 0.85% of Equillium worth $208,000 as of its most recent SEC filing. 27.05% of the stock is owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.